Checkpoint Immunotherapy for Melanoma and Advanced Cancer: Current and Novel Targets

Checkpoint Immunotherapy for Melanoma and Advanced Cancer: Current and Novel Targets

Dr. Jason Luke, assistant professor of medicine, explains the basic aspects as well as biomarkers of an effective antitumor immune response and reviews data from completed immunotherapy trials for melanoma and advanced cancers.  Dr. Luke also outlines novel drug targets and rational combination immunotherapy strategies


Published

May 19, 2016

Created by

The University of Chicago Medicine

Related Presenters

Luke

Jason Luke

Assistant Professor of Medicine

A medical oncologist, Jason Luke, MD, FACP, cares for patients with melanoma and advanced solid tumors. In the context of a multidisciplinary team of doctors and nurses, Dr. Luke works to bring a personalized approach to each patient through ...